Quarterly report pursuant to Section 13 or 15(d)

Related Party Transactions

Related Party Transactions
3 Months Ended
Mar. 31, 2018
Related Party Transactions [Abstract]  
Related Party Transactions

8. Related Party Transactions

During the three months ended March 31, 2018 and 2017, we paid $78,606 and $524,620 respectively, to Intrexon under the ECC agreements (See Note 7). Included in accounts payable and accrued expenses at March 31, 2018 and December 31, 2017 was $62,316 and $39,457, respectively, related to unpaid invoices received from Intrexon relating to work performed under the ECC Agreements. As of March 31, 2018 and 2017, Intrexon beneficially owned approximately 29.8% and 33.2%, respectively, of our outstanding common stock.

On June 27, 2016, the Company completed the sale of its consumer probiotics business to ProBiora Health, LLC (“ProBiora Health”), an entity owned by Ms. Christine L. Koski, a director at the time of the transaction. The purchase price was $1,700,000 in cash of which $1,250,000 was paid at closing and $450,000 was payable on or before July 31, 2016. The note accrued interest at the rate of 1% per annum and was paid in full on July 29, 2016. In connection with the sale, ProBiora Health assumed certain liabilities. ProBiora Health is obligated to pay the Company contingent consideration annually over a 10 year period based on a percentage of sales of products using the Purchased Assets, with a maximum obligation to the Company of $2,000,000. No such payment of contingent consideration was due to the Company from ProBiora Health for the years ending December 31, 2017 and December 31, 2016.

The activities related to the consumer probiotic business are reflected as part of “Discontinued Operations” for the periods presented.